Bridgefront Capital, LLC Clovis Oncology, Inc. Transaction History

Bridgefront Capital, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$4.06 - $5.8 $113,160 - $161,657	-27,872 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$5.02 - $7.05 $132,653 - $186,296	-26,425 Reduced 48.67%	27,872 $162,000
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $261,168 - $561,430	54,297 New	54,297 $381,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.